ESMO Congress 2022
Benefits of EpiSwitch CiRT
Now every patient can benefit from the world's first test to assess the probability of therapeutic success of checkpoint inhibitor therapy with high accuracy.
Understand your patient's likelihood of response to guide your decisions on beginning or continuing treatment with an ICI
Among patients experiencing an adverse reaction or toxicity, use the test to identify those who are likely to benefit from continued treatment
Improve overall patient response rate by accurately stratifying patients based on their likelihood of response
Fast and actionable prediction of a patient's personalized probability of response.
With a routine qPCR blood test, our comprehensive and validated approach delivers an easy-to-understand, confidential report that includes a prediction of individual patient response, with no need for a biopsy.
Patients with a positive EpiSwitch CiRT result can
begin or continue their
Built on Oxford BioDynamics' EpiSwitch technology platform, CiRT is based on a comprehensive and validated approach that identifies and stratifies critical drivers of an individual's immune system.
The predictive value of EpiSwitch CiRT blood signature was developed using Oxford BioDynamics' EpiSwitch 3D genomic immune health database—the world's largest genomic database—via several controlled studies conducted in 2018.START USING EpiSwitch CiRT
EpiSwitch CiRT Report
Personalize your guidance for each patient.
The test is intended to identify your patient's likelihood of response to an immune checkpoint inhibitor (ICI) therapy.
Individuals with a response level in the high probability range have a greater chance of benefiting from an ICI. Conversely, individuals with a response level in the low probability range have a reduced chance of benefiting from an ICI. These results should be considered along with other clinical features for interpretation by a licensed medical professional.
The EpiSwitch CiRT report includes indications for a healthcare professional to interpret a patient's likelihood of response to ICI therapy and formulate an effective management plan.DOWNLOAD SAMPLE REPORT
The EpiSwitch Checkpoint Inhibitor Response Test (CiRT) result for this specimen is in the High Likelihood of Response range to an ICI therapy. Individuals in the group have a greater chance of benefiting from an ICI agent. This result should be considered along with other clinical features for interpretation by a licensed medical professional.
The EpiSwitch Checkpoint inhibitor Response Test (CiRT) result for this specimen is in the Low Likelihood of Response range to an ICI therapy. This result should be considered along with other clinical features for interpretation by a licensed medical professional.
EpiSwitch CiRT is a validated test for predicting response to an ICI.
EpiSwitch CiRT delivers high sensitivity and specificity for predicting the beneficial use of an ICI. The blood test measures eight epigenetic markers to determine the most likely outcome of treatment.
Positive Predictive Value:
Negative Predictive Value:
Download the Technical Overview to learn more about how EpiSwitch CiRT can help guide treatment decisions for patients and their providers.TECHNICAL OVERVIEW
Are you interested in becoming an EpiSwitch CiRT testing center or registered EpiSwitch CiRT healthcare provider?
Contact CiRT Customer Service at 888-236-8896 to open an account, request EpiSwitch CiRT Requisition Forms, order EpiSwitch CiRT collection kits, or request further assistance relating to EpiSwitch CiRT. We look forward to speaking with you. If you are in the UK, please contact us at 01865 504932.
Frequently Asked Questions about EpiSwitch CiRT
How is EpiSwitch CiRT different from other cancer therapy tests?
The EpiSwitch CiRT is a first-of-its-kind blood test that gives healthcare professionals forward-looking information about an individual patient’s therapeutic response to checkpoint-inhibitor immunotherapy. EpiSwitch CiRT is a non-invasive blood test, it does not require any biopsy tissue. The test uses 3D genomic profiling rather than genomic mutation analysis. EpiSwitch CiRT predicts the likelihood of response based on an individual's genomic regulatory network.
Where is EpiSwitch CiRT performed?
EpiSwitch CiRT is performed in a CLIA-certified laboratory. Test results are securely reported to the ordering physician in 5 days or less after the lab receives the patient's blood sample.
Which individuals benefit most from EpiSwitch CiRT?
Patients whose physicians are considering them for checkpoint-inhibitor immunotherapy (ICI) will benefit from this test. EpiSwitch CiRT stratifies patients based on their likelihood of response to treatment with an ICI therapy. Patients at any stage of their cancer journey who are candidates for intervention with an ICI can benefit from EpiSwitch CiRT.
How will I receive the results of EpiSwitch CiRT?
EpiSwitch CiRT results are provided as a report that is delivered to the ordering physician via secure electronic communication or fax. Results will be available in approximately 3-5 days after the lab receives the patient's blood sample.
Can the results of EpiSwitch CiRT be sent directly to my patients?
No. To ensure doctor-patient confidentiality and maintain rigorous patient-data privacy standards, we securely provide EpiSwitch CiRT results directly to the ordering physician only.